Speratum Biopharma Inc. is a U.S.-based biopharmaceutical company formally founded in 2021, with corporate headquarters in Dover, Delaware, and R&D operations in San José, Costa Rica and Houston, Texas. We are dedicated to transforming the treatment of aggressive and resistant cancers through the development of next-generation RNA-based therapeutics.

While our scientific foundation began in 2014 with pioneering research led by Dr. Christian Marín-Müller, it was in 2021 that Speratum Biopharma transitioned from an academic and incubator-led initiative into a commercially focused company. This milestone marked our incorporation in the United States, the establishment of structured corporate governance, and the launch of our clinical and translational development strategy.

At Speratum, we are building a robust pipeline around a proprietary RNA interference (RNAi) platform that targets key oncogenic drivers in solid tumors. Our technologies integrate modular synthetic RNA molecules with advanced delivery systems, enabling multi-target engagement with enhanced tumor specificity and therapeutic precision. These capabilities position Speratum at the forefront of RNA-based oncology innovation.

In alignment with our mission to “deliver hope through innovative cancer therapeutics,” we are proud to share that Speratum Biopharma has joined Johnson & Johnson Innovation’s JLABS @ Texas Medical Center (TMC), the largest global network of open innovation ecosystems. As a resident company, we benefit from unparalleled access to Johnson & Johnson’s scientific, regulatory, and venture-building expertise. This collaboration empowers us to accelerate development, enhance strategic partnerships, and deepen our impact across the pharmaceutical and medical technology sectors.

We are more than a biotech company—we are a mission-driven organization advancing the science of healing through the power of RNA, with a global team committed to creating tangible outcomes for patients in need.